Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.77 |
| ▸ | BCR | P11274 | 15/20 | 0.77 |
| ▸ | KIT | P10721 | 11/20 | 0.77 |
| ▸ | ABL2 | P42684 | 6/20 | 0.77 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.77 |
| ▸ | LYN | P07948 | 3/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.77 |
| ▸ | SRC | P12931 | 2/20 | 0.77 |
| ▸ | SYK | P43405 | 2/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | DDX3X | O00571 | 1/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.77 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.77 |
| ▸ | CA2 | P00918 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27935065 | 0.91 | ABL1 (0.78) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL6417929 | 0.89 | ABL1 (0.77) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL13845837 | 0.88 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL15477704 | 0.87 | ABL1 (0.59) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.87 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.87 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29351601 | 0.87 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL4882244 | 0.87 | ABL1 (0.83) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.87 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.86 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222360-A1 | Treatment of Malignant Peripheral Nerve Sheath Tumors | KINKI UNIVERSITY (JP) | 2010-09-02 | — | — | US | claimed |
| EP-1487424-B1 | 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-(4-METHYL-3(4-PYRIDIN-3-YL)PYRIMIDIN-2-YL-AMINO)PHENYL)-BENZAMIDE FOR TREATING ANG II-MEDIATED DISEASES | NOVARTIS AG (CH) | 2006-09-13 | — | — | EP | disclosed |
| EP-1487424-A2 | 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-(4-METHYL-3(4-PYRIDIN-3-YL)PYRIMIDIN-2-YL-AMINO)PHENYL)-BENZAMIDE FOR TREATING ANG II-MEDIATED DISEASES | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077892-A3 | 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3(4-PYRIDIN-3-YL)PYRIMIDIN-2-YL-AMINO)PHENYL]-BENZAMIDE FOR TREATING ANG II-MEDIATED DISEASES | NOVARTIS AG (CH) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003077892-A2 | 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3(4-PYRIDIN-3-YL)PYRIMIDIN-2-YL-AMINO)PHENYL]-BENZAMIDE FOR TREATING ANG II-MEDIATED DISEASES | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222360-A1 | Treatment of Malignant Peripheral Nerve Sheath Tumors | BRAF, NRAS, MAPK1 | ABL1 213/4885BCR 1238/4885KIT 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.